How many drugs treat Dermatographic urticaria?

Drug Landscape tracks 10 marketed treatments for Dermatographic urticaria (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/dermatographic-urticaria.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dermatographic urticaria — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dermatographic urticaria (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Dermatographic urticaria, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Phenazoline	ANTAZOLINE	Novartis	antazoline	Histamine H1 receptor	1990-01-01
Actidil	TRIPROLIDINE	Novartis	triprolidine	Histamine H1 receptor	1983-01-01
Hispril	DIPHENYLPYRALINE	GSK	diphenylpyraline	Histamine H1 receptor	1982-01-01
Karbinal Er	CARBINOXAMINE	Mcneil	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1974-01-01
Pyrilamine	mepyramine	Impax Labs	Central Nervous System Stimulant [EPC]	Histamine H1 receptor	1973-01-01
Drixoral	DEXBROMPHENIRAMINE	Merck & Co.	dexbrompheniramine	Histamine H1 receptor	1963-01-01
Hydroxyzine Hydrochloride	HYDROXYZINE	Pfizer	Antihistamine	Histamine H1 receptor	1956-01-01
Tussionex Pennkinetic	CHLORPHENIRAMINE MALEATE	Bayer	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1950-01-01
Tussionex Pennkinetic	chlorphenamine	Bayer	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1950-01-01
Unisom	DOXYLAMINE	Chattem	Antihistamine	Histamine H1 receptor	1948-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Dermatographic urticaria
Novartis · 3 drugs in Dermatographic urticaria
Bayer · 2 drugs in Dermatographic urticaria
Impax Labs · 1 drug in Dermatographic urticaria
King Faisal Specialist Hospital & Research Center · 1 drug in Dermatographic urticaria
Mcneil · 1 drug in Dermatographic urticaria
Merck & Co. · 1 drug in Dermatographic urticaria
Pfizer · 1 drug in Dermatographic urticaria
St. Petersburg Bekhterev Research Psychoneurological Institute · 1 drug in Dermatographic urticaria
Technical University of Munich · 1 drug in Dermatographic urticaria
Chattem · 1 drug in Dermatographic urticaria
GSK · 1 drug in Dermatographic urticaria

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Dermatographic urticaria:

Cite this brief

Drug Landscape (2026). Dermatographic urticaria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dermatographic-urticaria. Accessed 2026-06-10.

Dermatographic urticaria full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing